PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Current Quarter	$-0.8	Next Quarter	$-0.8
Current Year	$-3.19	Next Year	$-3.19
QoQ Growth	+0.0%	YoY Growth	+0.0%
3Y EPS CAGR	+76.8%	Target Price	$16.00
Consensus	Buy	Upside	+160.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PAVM	$6.14	-3.91%	13.11K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PAVM	$6.14	-3.9%	13.11K
3
4
5
6

PAVM

PAVM

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get PAVmed Inc. Data in Excel

Get PAVmed Inc. Data in Excel